|
The Tenovus Sing For Life Choir perform at the National Cancer Resarch Institute Conference at the BT Convention Centre, Liverpool, 7.11.10. A truly remarkable choir made up of people who have been affected by cancer; the Sing for Life Choir was established in January, initially as a research project to measure the health and psychosocial benefits of singing for cancer patients and their familes and has since developed into a strong support network for its members who now meet on a weekly basis in the South Wales Valleys to learn new fun songs and rehearse for regular performances. Tenovus' motivation for setting up the choir was to give those who have been affected by cancer a space to come together in a fun, positive and energetic way and focus on something other than their cancer.However, research carried out by Cardiff University has also shown that the choir can have significant benefits for improving the health and wellbeing of those who take part in it.  The Tenovus Sing for Life Choir is open to anyone who has experienced cancer; its members include family, carers and friends as well as cancer patients. The choir is run in partnership with the motivational and team building company Sing and Inspire who ensure that the choir practices are always fun and inclusive, whilst also shaping the choir into top class live act! For more information on the Tenovus Sing For Life Choir please contact Dr Ian Lewis, Head of Research for Tenovus on 02920 768850 or at ian.lewis@tenovus.org.uk
|
Video Length: 0
Date Found: January 20, 2011
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|